Insider Transactions in Q2 2021 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,310
-8.79%
|
$11,550
$5.89 P/Share
|
|
Jun 30
2021
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,883
+23.07%
|
-
|
|
Jun 30
2021
|
Andrew Paul Mazar Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
942
-5.1%
|
$4,710
$5.89 P/Share
|
|
Jun 30
2021
|
Andrew Paul Mazar Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,212
+14.81%
|
-
|
|
Jun 30
2021
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
823
-23.55%
|
$4,115
$5.89 P/Share
|
|
Jun 30
2021
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,442
+41.14%
|
-
|
|
Jun 30
2021
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+8.8%
|
-
|
|
Jun 30
2021
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+0.35%
|
-
|
|
Jun 30
2021
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+16.55%
|
-
|
|
Jun 30
2021
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+21.22%
|
-
|